Emerging treatment options for patients with recurrent advanced thymic epithelial tumors

被引：1
作者：
Evans, Tracey L. [1 ]
机构：
[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
ONCOTARGETS AND THERAPY | 2012年 / 5卷
关键词：
thymoma; thymic carcinoma; targeted therapy; epidermal growth factor receptor; AUTOIMMUNE REGULATOR AIRE; FACTOR-I RECEPTOR; PHASE-II; MUTATIONAL STATUS; THYMOMA; KIT; CARCINOMA; CHEMOTHERAPY; EXPRESSION; PACLITAXEL;
D O I：
10.2147/OTT.S23267
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The purpose of this review article is to review recent advances in the treatment of advanced thymic epithelial tumors. These tumors are generally responsive to cytotoxic combination chemotherapy in the first-line setting. While newer agents have shown efficacy in the salvage setting, there is no one standard approach. A multitude of targeted agents have shown promise generally in case reports, though as of yet, nothing has shown consistent benefit. Because of the rarity of thymic epithelial tumors, clinical trial enrollment is difficult but nevertheless essential.
引用
收藏
页码：177 / 184
页数：8
相关论文
共 62 条
  • [1] Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone An Eastern Cooperative Oncology Group Study
    Aisner, Seena C.
    Dahlberg, Suzanne
    Hameed, Meera R.
    Ettinger, David S.
    Schiller, Joan H.
    Johnson, David H.
    Aisner, Joseph
    Loehrer, Patrick J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : 885 - 892
  • [2] Allander SV, 2001, CANCER RES, V61, P8624
  • [3] [Anonymous], J CLIN ONCOL S
  • [4] Basha AM, 2004, 38 AM SOC CLIN ONC A
  • [5] A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma
    Bedano, P. M.
    Perkins, S.
    Burns, M.
    Kessler, K.
    Nelson, R.
    Schneider, B. P.
    Risley, L.
    Dropcho, S.
    Loehrer, P. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma
    Bisagni, Giancarlo
    Rossi, Giulio
    Cavazza, Alberto
    Sartori, Giuliana
    Gardini, Giorgio
    Boni, Corrado
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (06) : 773 - 775
  • [7] EST-2582 PHASE-II TRIAL OF CISPLATIN IN METASTATIC OR RECURRENT THYMOMA
    BONOMI, PD
    FINKELSTEIN, D
    AISNER, S
    ETTINGER, D
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (04): : 342 - 345
  • [8] Response of malignant thymoma to erlotinib
    Christodoulou, C.
    Murray, S.
    Dahabreh, J.
    Petraki, K.
    Nikolakopoulou, A.
    Mavri, A.
    Skarlos, D.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (07) : 1361 - 1362
  • [9] Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation
    Disel, Umut
    Oztuzcu, Serdar
    Besen, Ali Ayberk
    Karadeniz, Cemile
    Kose, Fatih
    Sumbul, Ahmet Taner
    Sezer, Ahmet
    Nursal, Gul Nihal
    Abali, Huseyin
    Ozyilkan, Ozgur
    [J]. LUNG CANCER, 2011, 71 (01) : 109 - 112
  • [10] Epidemiology of Thymoma and Associated Malignancies
    Engels, Eric A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 : S260 - S265
1234567